Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. develops clinical-stage biotechnology programs for mental health conditions, with news centered on investigational therapies for treatment-resistant depression and social anxiety disorder. Recurring updates cover BPL-003, a mebufotenin benzoate nasal spray with FDA Breakthrough Therapy Designation for treatment-resistant depression; VLS-01, a DMT buccal film; and EMP-01, an oral R-MDMA program for social anxiety disorder.
Company announcements also address peer-reviewed clinical data, FDA interactions, patient-participant research practices, financial results, R&D spending, acquisition-related integration with Beckley Psytech, equity index inclusion, and capital runway disclosures. The news flow reflects a clinical-stage issuer whose operating updates are tied primarily to psychiatry-focused development programs, regulatory engagement, and financing capacity.
AtaiBeckley (NASDAQ: ATAI) reported positive topline results from a Phase 2a trial of EMP-01 (oral R-MDMA) in adults with Social Anxiety Disorder on February 26, 2026. The study met its primary safety objective with no serious adverse events and high retention.
EMP-01 showed a placebo-adjusted LSAS reduction of 11.85 points at Day 43 (Hedges’ g=0.45; p=0.036 one-tailed), 49% CGI‑I responders vs. 15% placebo (NNT 2.95). Seventy-one patients enrolled across seven UK sites; detailed analyses will appear at scientific venues.
AtaiBeckley (NASDAQ: ATAI) will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will include presentations and live Q&A with the company’s executive leadership and external key opinion leaders.
Investors, analysts, and media may register for the live webcast; a replay will be posted afterward on the company’s investor website under Events.
AtaiBeckley (NASDAQ: ATAI) appointed Michael Faerm as Chief Financial Officer effective March 9, 2026. Faerm brings more than 25 years of finance, equity research and banking experience and will lead financial strategy, capital markets and operations. Anne Johnson will transition to Chief Accounting Officer to preserve continuity. The company noted BPL-003 is advancing toward Phase 3 as its clinical programs progress.
AtaiBeckley (NASDAQ: ATAI) said its CEO Srinivas Rao, M.D., Ph.D., and VP of Investor Relations Jason Awe, Ph.D., will attend investor conferences in March 2026 with fireside chats and one-on-one meetings.
Events: TD Cowen (Boston) on March 4 with a fireside chat 11:50am–12:20pm EST; Jefferies Biotech on March 10 (one-on-ones) in Miami; Leerink (Miami) on March 11 with a fireside chat 8:00am–8:30am EST. Live webcasts of the fireside chats will be available on the company's investor site and archived for at least 30 days.
AtaiBeckley (NASDAQ: ATAI) presented new clinical and preclinical data at the 64th Annual ACNP Meeting (Jan 12–15, 2026) in Nassau, Bahamas. A Phase 2b double-blind study of intranasal BPL-003 (mebufotenin benzoate) showed that a single 8 mg or 12 mg dose produced a significant, rapid, and sustained antidepressant effect versus a 0.3 mg sub-perceptual control at all timepoints, with both active doses reported as well-tolerated. The BPL-003 poster was selected for the Hot Topics Session. A separate preclinical poster on 5-MeO-DMT reported pharmacology, pharmacokinetics, and potential neuroplasticity-relevant effects supporting further investigation. The company said these results support moving toward Phase 3 evaluation for BPL-003.
AtaiBeckley (NASDAQ: ATAI) provided a 2026 outlook ahead of the J.P. Morgan Healthcare Conference and highlighted clinical progress, corporate changes, and upcoming milestones.
Key clinical updates: positive Phase 2b topline results for BPL-003 (mebufotenin benzoate) in TRD with single-dose durable effects; OLE data supporting a 12 mg repeat dose; Phase 3 guidance expected in Q1’26 with potential initiation in Q2’26 pending an FDA End-of-Phase 2 meeting. Additional 2026 catalysts include H2’26 topline readout for VLS-01 and Q1’26 topline data for EMP-01. Corporate: redomiciled to the U.S., added to the NASDAQ biotech index, and expects funding into 2029.
AtaiBeckley (NASDAQ: ATAI) completed the redomiciliation of its parent from a Netherlands company to a Delaware corporation, effective after market close on Dec 30, 2025. All issued ordinary shares were exchanged on a one-for-one basis for newly issued common stock of AtaiBeckley Inc.
The redomiciliation was approved by approximately 99% of votes cast at the extraordinary general meeting on Nov 4, 2025. The company said it expects cost savings, simplified corporate structure, alignment with its U.S. listing and shareholder base, streamlined reporting and reduced administrative burden. Common stock will continue trading on NASDAQ under the symbol ATAI. For further details, see the company filings with the SEC.
AtaiBeckley (NASDAQ: ATAI) said its common stock was added to the NASDAQ Biotechnology Index (NBI), effective prior to market open on Dec 22, 2025. The company cited progress in 2025 including approximately $300 million of capital raised, advancement of multiple clinical programs toward late‑stage development, a strategic combination between atai Life Sciences and Beckley Psytech, and an expected U.S. corporate domiciliation around year‑end.
The NBI tracks Nasdaq‑listed biopharma securities meeting market‑cap, trading volume, and seasoning criteria and is selected annually in December; inclusion can increase visibility among index funds and institutional investors.
AtaiBeckley (NASDAQ: ATAI) announced a U.S. patent grant (No. 12,492,178) for EMP-01 (oral R‑MDMA), which the company says provides exclusivity through 2043. The patent covers a highly crystalline HCl salt form with high aqueous solubility and low hygroscopicity, attributes cited as beneficial for formulation, manufacture, and storage.
The company states this strengthens its intellectual property estate and supports advancement of EMP-01 toward clinical development; topline data from an exploratory Phase 2a study in adults with social anxiety disorder is expected in Q1 2026.
Enhanced (ATAI) announced a major leadership reshuffle on Nov 19, 2025, naming Co‑founder Maximilian Martin as CEO and Co‑founder Christian Angermayer as Executive Chairman while Jim Murren joins the board.
Enhanced also appointed Sid Banthiya as CFO, promoted Alex Lopez to Chief Brand Officer and Rick Adams to Chief Sporting Officer, and named Chris Jones Chief Communications Officer. Background highlights include Martin's prior company sale in a €400 million transaction and Angermayer's family office overseeing $7 billion AUM.